综合代谢学科学在阿尔茨海默病:相关性和未来的前景
Simone Lista1, Raúl González-Domínguez2, Susana López-Ortiz1
1i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid, Spain.
Ageing research reviews
|June 21, 2023
概括
代谢学揭示了阿尔茨海默病 (AD) 发病的早期代谢变化,特别是在脂质代谢中,有助于生物标志物发现和早期诊断. 需要进一步的研究来区分因果代谢变化和补偿性变化.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 系统生物学 系统生物学
背景情况:
- 阿尔茨海默病 (AD) 涉及复杂的病理生理机制,在临床症状出现前几十年就开始.
- 在AD中被破坏的分子和细胞通路需要先进的技术,如奥米克科学来阐明病原体.
研究的目的:
- 批判性地审查用于识别新型AD生物标志物的代谢学方法.
- 通过代谢分析来加深对AD病理生理机制的理解.
主要方法:
- 使用高通量,无偏见的奥米克科学,特别是代谢学.
- 在生物样本中同时检测和量化扰乱的代谢物.
- 分析与AD相关的代谢网络波动.
主要成果:
- 代谢学一直将脂质代谢的变化确定为AD病变的关键特征.
- 代谢变化可能会先于AD的临床发病,为早期检测提供了潜力.
结论:
- 代谢学与现有生物标志物相结合,可以支持早期AD诊断和个性化治疗策略.
- 在阿尔茨海默病研究中,区分因果代谢变化与表现性或补偿性变化仍然是一个挑战.
更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
544
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
01:22Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223